Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program

Abstract

Background Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA). Methods The SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of >20 antimicrobials against 191 460 clinical S. aureus isolates collected from 427 centers in 45 countries from 1997 to 2016. Each center contributed isolates and clinical data for consecutive episodes of bacteremia, pneumonia in hospitalized patients, urinary tract infection, and skin and skin structure infection. Results Overall, 191 460 S. aureus isolates were collected, of which 77 146 (40.3%) were MRSA, varying geographically from 26.8% MRSA in Europe to 47.0% in North America. The highest percentage of MRSA was in nosocomial isolates from patients aged >80 years. Overall, MRSA occurrences increased from 33.1% in 1997–2000 to a high of 44.2% in 2005–2008, then declined to 42.3% and 39.0% in 2009–2012 and 2013–2016, respectively. S. aureus bacteremia had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005–2008 and then declining. Vancomycin activity against S. aureus remained stable (minimum inhibitory concentration [MIC]90 of 1 mg/L and 100% susceptibility in 2016; no increase over time in isolates with a vancomycin MIC >1 mg/L). Several agents introduced during the surveillance period exhibited in vitro potency against MRSA. Conclusions In a large global surveillance program, the rise of MRSA as a proportion of all S. aureus peaked a decade ago and has declined since, consistent with some regional surveillance program reports. Vancomycin maintained high activity against S. aureus, and several newer agents exhibited excellent in vitro potencies.

Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018

“…7 7-79 For instance, recent reporting for more than 190 000 S aureus isolates collected worldwide over 20 years in SENTRY demonstrated a decrease in the incidence of MRSA infection from 44.2% (2005-2008) to 39.0% (2013-2016), with the highest proportion of MRSA infection observed among patients older than 80 years; 80% of MRSA isolates were concurrently resistant to ciprofloxacin. 77 Likewise, penicillin resistance among more than 65 000 S pneumoniae isolates fluctuated by region over the 20-year study period, with g l o b a l re s i s t a n c e r ate s o f 3 4 . 2 % i n t h e l a s t ye a r s (2015-2016) 78 ; however, ciprofloxacin resistance among P aeruginosa isolates was higher in SENTRY 79 than in our study.…”

Novel spa and Multi-Locus Sequence Types (MLST) of Staphylococcus Aureus Samples Isolated from Clinical Specimens in Korean

“…Methicillin-resistant Staphylococcus aureus (MRSA) is a prominent pathogen that causes severe infections in both healthcare and community settings [1]. MRSA is associated with considerable infection worldwide [2].…”

Anthra[1,2-d][1,2,3]triazine-4,7,12(3H)-triones as a New Class of Antistaphylococcal Agents: Synthesis and Biological Evaluation

“…Over the past decades, this bacterium has become the main cause of bloodstream infections (BSI) in the world, with a mortality level of 20-40% [5]. Recent advances in the developments of antistaphylococcal agents are presented in works on search of new non-antibiotic agents: peptidoglycan hydrolases compounds of plant origin (plant extracts, essential oils and their components) [6][7][8][9], vaccines development [8], silver nanoparticles [10], bacteriocins [11], and bacteriophages [12]. Currently, the most reasonable approach for understanding the crucial cellular pathways by which unknown to date (or not used as antimicrobial agents) molecules affect pathogenic microorganisms at a molecular level seems to be transcriptome analysis.…”